- Home
- ECOR vs TCRX Comparison
ECOR vs TCRX Comparison
Compare ECOR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | TCRX |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 67.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECOR | TCRX |
|---|---|---|
| Price | $6.16 | $0.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $7.00 |
| AVG Volume (30 Days) | 81.0K | ★ 888.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | $10,325,000.00 |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 27.20 | ★ 266.65 |
| 52 Week Low | $4.16 | $0.83 |
| 52 Week High | $10.50 | $2.57 |
Technical Indicators
Market Signals| Indicator | ECOR | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 37.24 |
| Support Level | $5.69 | N/A |
| Resistance Level | $7.35 | $1.21 |
| Average True Range (ATR) | 0.66 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 17.60 | 0.81 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.